The Quantellect read.As of Nov 19, 2026, 14 active firms cover Apellis Pharmaceuticals Inc: 3 rate it Buy or better, 11 sit at Neutral, and 0 rate it Sell or worse, a neutral consensus. Targets range widely, $18.00 to $48.00 (about 2.7x), a sign of real disagreement on valuation. The average target of $34.69 sits 1095% above the current $2.90. Sentiment has drifted a little more constructive lately, with Sell ratings easing from 1 to 0 over recent months. On the fundamentals, the Street sees revenue growth near -8% this year and 11% next, consensus EPS building from about $-0.26 next quarter toward $-0.22 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS14 active firms
Neutral
Strong Buy00%
Buy321%
Neutral1179%
Sell00%
Strong Sell00%
Based on 14 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$34.69
+1095.3% upside
Average target across 13 active firms as of Nov 19, 2026 vs $2.90 current
Highest Target$48.00
Average Target$34.69
Lowest Target$18.00
Detailed analyst forecasts for APLS
Showing 1–14 of 14 named analysts shown · 14 active firms in the rating projection
As of Nov 19, 2026, 3 of 14 active firms rate APLS a Buy (11 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
APLS EPS & revenue forecast
EPS · NEXT QUARTER
$-0.26
Range $-0.60 – $-0.10 · 12 analysts · -116% YoY
Next period, 12 analysts expect Apellis Pharmaceuticals Inc to earn $-0.26 a share (range $-0.60 – $-0.10), versus $1.67 a year earlier. Full-year consensus is $-1.13, growing to $-0.22 the year after.
REVENUE · NEXT QUARTER
$218.7M
Range $207.2M – $233.5M · 12 analysts · -52% YoY
Revenue is expected to reach $218.7M (range $207.2M – $233.5M), -52.0% year-over-year. Full-year consensus is $925.4M, rising to $1.0B next year.
Top analysts covering Apellis Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on APLS.
#1
Laura Chico
Wedbush · Rank #55
Neutral
$18.00+520.2% to target
Overall win rate
46%
+ Follow
#2
Luca Issi
RBC Capital · Rank #76
Neutral
$18.00+520.2% to target
Overall win rate
49%
+ Follow
#3
Anupam Rama
JP Morgan · Rank #171
Neutral
$41.00+1312.6% to target
Overall win rate
48%
+ Follow
#4
Greg Harrison
Scotiabank · Rank #223
Neutral
$22.00+658.0% to target
Overall win rate
38%
+ Follow
#5
Graig Suvannavejh
Mizuho · Rank #239
Neutral
$41.00+1312.6% to target
Overall win rate
40%
+ Follow
APLS stock forecast FAQ
What is APLS's average 12-month price target?+
The 13 active firms with a live target average $34.69 for Apellis Pharmaceuticals Inc over the next 12 months, ranging from a $48.00 high to a $18.00 low, as of Nov 19, 2026.
Is APLS stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 14 active firms as of Nov 19, 2026, 3 rate it Buy or Strong Buy, 11 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for APLS?+
The Street-high target is $48.00 (Stifel), and the Street-low is $18.00 (Wedbush). The average of all 13 active-firm targets is $34.69.
How many active Wall Street firms cover APLS?+
14 active firms have a recognized rating on Apellis Pharmaceuticals Inc as of Nov 19, 2026, and 13 active firms carry a live 12-month price target.
Who is the most accurate analyst covering APLS?+
Among analysts who currently cover APLS, Laura Chico of Wedbush has the strongest overall Quantellect track record (Rank #55). Their current call is Neutral with a $18.00 target.
What is Apellis Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.26 per share (range $-0.60 – $-0.10) across 12 analysts. Full-year EPS is projected at $-1.13, rising to $-0.22 the following year.
How much revenue is Apellis Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $218.7M (range $207.2M – $233.5M). Full-year revenue is projected at $925.4M, growing to $1.0B next year.
Have analysts been upgrading or downgrading APLS lately?+
As of Nov 19, 2026, 3 of 14 active firms rate APLS a Buy (11 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their APLS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.